Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000364916

Medchemexpress LLC Elimusertib (BAY 1895344) | 1876467-74-1 | 99.7% | 375.43 | 100 MG
SDP

Catalog No. 5000364916
Encompass_Preferred

Elimusertib (BAY-1895344) is a potent, orally active, and selective ATR inhibitor with an IC50 of 7 nM. It demonstrates anti-tumor activity and is suitable for research into solid tumors and lymphomas.

  • Potently inhibits proliferation of human tumor cell lines.
  • Suppresses hydroxyurea-induced H2AX phosphorylation.
  • Exhibits high selectivity against mTOR, DNA-PK, ATM, and PI3K.
  • Shows potent antiproliferative activity against various cancer cell lines.
  • Demonstrates potent anti-tumor efficacy in monotherapy in xenograft models of ovarian and colorectal cancer.
  • Causes complete tumor remission in mantle cell lymphoma models.
  • Has synergistic antitumor activity when combined with Carboplatin in platinum-resistant human CRC PDX models.
  • Exhibits moderate oral bioavailability and short elimination half-lives.

Catalog No. 50-003-64916 Supplier Medchemexpress LLC Supplier No. 100MGHY101566
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

Elimusertib (BAY-1895344) is a potent, orally active, and selective ATR inhibitor with an IC50 of 7 nM. It demonstrates anti-tumor activity and is suitable for research into solid tumors and lymphomas.

  • Potently inhibits proliferation of human tumor cell lines.
  • Suppresses hydroxyurea-induced H2AX phosphorylation.
  • Exhibits high selectivity against mTOR, DNA-PK, ATM, and PI3K.
  • Shows potent antiproliferative activity against various cancer cell lines.
  • Demonstrates potent anti-tumor efficacy in monotherapy in xenograft models of ovarian and colorectal cancer.
  • Causes complete tumor remission in mantle cell lymphoma models.
  • Has synergistic antitumor activity when combined with Carboplatin in platinum-resistant human CRC PDX models.
  • Exhibits moderate oral bioavailability and short elimination half-lives.

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.